BLOOD PRESSURE REDUCTION IN THE MORNING YIELDS BENEFICIAL EFFECTS ON PROGRESSION OF CHRONIC RENAL INSUFFICIENCY WITH REGRESSION OF LEFT VENTRICULAR HYPERTROPHY

REFERENCES

• Levin A., Singer J., Thompson C., Ross M., Lewis M. Prevalent Left Ventricular Hypertrophy in the Predialysis Population: Identifying Opportunities for Intervention. Am. J. Kidney Dis. 1996; 27: 347–354
   PubMed Web of Science ®Google Scholar
• Amann K., Rychlik L., Miltenberger-Milteny G., Ritz E. Left Ventricular Hypertrophy in Renal Failure. Kidney Inter. 1998; 54(Suppl. 68)S-78–S-85
   Google Scholar
• Cruickshnak J. M., Lewis J., Moore V., Dodd C. Reversibility of Left Ventricular Hypertrophy by Differing Types of Antihypertensive Therapy. J. Human Hypertens. 1992; 6: 85–90
   PubMed Web of Science ®Google Scholar
• Frohlich E. Current Approaches in the Treatment of Hypertension. Curr. Problems in Cardiol. 1994; 19: 397–472
   Google Scholar
• Phillips R., Diamond J. Ambulatory Blood Pressure Monitoring and Echocardiography–Noninvasive Techniques for Evaluation of the Hypertensive Patient. Prog. Cardiovasc. Dis. 1999; 41: 397–440
   PubMed Web of Science ®Google Scholar
• Mansoor G., White W. Ambulatory Blood Pressure Monitoring is a Useful Clinical Tool in Nephrology. Am. J. Kidney Dis. 1997; 30: 591–605
   PubMed Web of Science ®Google Scholar
• Mancia G., Canchetti A., Agebiti-Rosei E. Ambulatory Blood Pressure is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy. Circulation 1997; 95: 1464–1470
   PubMed Web of Science ®Google Scholar
• Mengden T., Binswanger B., Spuhler T., Weisser B., Vetter W. The Use of Self-measured Blood Pressure Determinations in Assessing Dynamics of Drug Compliance in a Study with Amlodipine Once a Day, Morning Versus Evening. J. Hypertens. 1993; 11: 1403–1411
   PubMed Web of Science ®Google Scholar
• Rave K., Bender R., Heise T., Sawicki P. Value of Blood Pressure Self-monitoring as a Predictor of Progression of Diabetic Nephropathy. J. Hypertens. 1999; 17: 597–601
   PubMed Web of Science ®Google Scholar
• Yarows S. A., Julius S., Pickering T. Home Blood Pressure Monitoring. Arch. Intern. Med. 2000; 160: 1248–1260
   Google Scholar
• Thijs L., Staessen J., Celis H., et al. Reference Values for Self-recorded Blood Pressure. Arch. Intern. Med. 1998; 158: 481–488
   PubMed Web of Science ®Google Scholar
• Ibrahim M., Tarazi R., Dustan H., Gifford R., Jr. Electrocardiogram in Evaluation of Resistance to Antihypertensive Therapy. Arch. Intern. Med. 1997; 137: 1125–1129
   Google Scholar
• Portaluppi F., Montanari L., Massari M., Di Chiara V., Capanna M. Loss of Nocturnal Decline of Blood Pressure in Hypertension Due to Chronic Renal Failure. Am. J. Hypertens. 1991; 4: 20–26
   PubMed Web of Science ®Google Scholar
• Cottone S., Panepinot N., Vadala A., et al. Sympathetic Overactivity and 24-hour Blood Pressure Pattern in Hypertensives with Chronic Renal Failure. Renal. Fail. 1995; 17: 751–758
   PubMed Web of Science ®Google Scholar
• Kario K., Schwartz J., Pickering T. Changes of Nocturnal Blood Pressure Dipping Status in Hypertensive by Nighttime Dosing of α-Adrenergic Blocker, Doxazosin. Results from the Halt Study. Hypertension 2000; 35: 787–794
   PubMed Web of Science ®Google Scholar
• Mosley C., O'Connor D., Taylor A., Slutsky R., Cervenka J. Comparative Effects of Antihypertensive Therapy with Guanabenz and Propranolol on Renal Vascular Resistance and Left Ventricular Mass. J. Cardiovasc. Pharmacol. 1984; 6: S757–S761
   Google Scholar
• Packer M., O'Conner C., Ghali J., et al. For the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of Amlodipine on Morbidity and Mortality in Severe Congestive Heart Failure. N. Engl. J. Med. 1996; 335: 1107–1114
   PubMed Web of Science ®Google Scholar
• Maschio G., Alberti D., Janin G., et al. Effect of the Angiotensin Converting-enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. N. Engl. J. Med. 1996; 334: 939–945
   PubMed Web of Science ®Google Scholar
• Bakris G., Weir M. Angiotensin-converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine. Arch. Intern. Med. 2000; 160: 685–693
   PubMed Web of Science ®Google Scholar
• Fogari R., Zoppi A., Mugellini A., Lusardi P., Destro M., Corradi L. Effect of Benazepril Plus Amlodipine vs Benazepril Alone on Urinary Albumin Excretion in Hypertensive Patients with Type II Diabetes and Microalbuminuria. Clin. Drug. Invest. 1997; 13(Suppl. 1)50–55
   Google Scholar
• Baum T., Shropshire A. Studies on the Centrally Mediated Hypotensive Activity of Guanabenz. Eur. J. Pharmacol. 1976; 37: 31–44
   PubMed Web of Science ®Google Scholar
• Devereux R., Reichek N. Echocardiographic Determination of Left Ventricular Mass in Man. Ciculation 1977; 55: 1325–1350
   Google Scholar
• Greaves S., Gamble G., Collins J., Whalley G., Sharpe D. Determinants of Left Ventricular Hypertrophy and Systolic Dysfunction in Chronic Renal Failure. Am. J. Kidney Dis. 1994; 24: 768–776
   PubMed Web of Science ®Google Scholar
• Gustafsson F., Kober L., Torp-Pedersen C., et al. Long-term Prognosis after Acute Myocardial Infarction in Patients with a History of Arterial Hypertension. TRACE Study Group. Eur. Heart J. 1998; 19: 588–594
   PubMed Web of Science ®Google Scholar
• Pfeffer M., Braunwald E., Moye L., et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction; Results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. 1992; 327: 669–677
   PubMed Web of Science ®Google Scholar
• Rambausek M., Mall G., Kollmar S., Ritz E. Effect of Converting Enzyme Inhibitors on Cardiac Changes in Experimental Uremia. Kidney Inter. 1988; 34(Suppl. 25)201–203
   Google Scholar
• Roithinger F., Punzengruber C., Wallner M., et al. The Influence of ACE-Inhibition on Myocardial Mass and Diastolic Function in Chronic Hemodialysis Patients with Adequate Control of Blood Pressure. Clin. Nephrol. 1994; 42: 309–314
   PubMed Web of Science ®Google Scholar
• Dyadyk A., Bagriy A., Lebed I., Yarovaya N., Schukina E., Taradin G. ACE Inhibitors Captopril and Enalapril Induce Regression of Left Ventricular Hypertrophy in Hypertensive Patients with Chronic Renal Failure. Nephrol. Dial. Transplant. 1997; 12: 945–951
   PubMed Web of Science ®Google Scholar
• Sowers J. Comobidity of Hypertension and Diabetes: The Fosionpril Versus Amlodipine in Cardiovascular Events Trial. Am. J. Cardiol. 1998; 82(9B)15R–19R
   Google Scholar
• Kribbs S., Merritt W., Clair M., et al. Amlodipine Monotherapy, Angiotensin-converting Enzyme Inhibition, and Combination Therapy with Pacing-induced Heart Failure. Hypertension 1998; 31: 755–765
   PubMed Web of Science ®Google Scholar
• Klingbeil A. U., Schmieder R. E. Not All Left Ventricular Hypertrophy is Created Equal. Nephrol. Dial. Tranplant. 1999; 14: 2803–2805
   PubMed Web of Science ®Google Scholar
• Dequattro V., Lee D., Allen J., Sirgo M., Plachetka J. Labetalol Blunts Morning Pressor Surge in Systolic Hypertension. Hypertension 1988; 11: 1198–1201
   Google Scholar
• James G., Pickering T., Yee L., Harshfield G., Riva S., Laragh J. The Reproducibility of Average Ambulatory, Home, and Clinic Pressures. Hypertension 1988; 11: 545–549
   PubMed Web of Science ®Google Scholar
• Baumgart P., Walger P., Gemen S., von Eiff M., Raidt H., Rahn K. Blood Pressure Elevation During the Night in Chronic Renal Failure, Hemodialysis and after Renal Tranplantation. Nephron 1991; 57: 293–298
   PubMed Web of Science ®Google Scholar
• Morduchowicz G., Zabludowski J., Wittenberg C., Winkler J., Boner G. Ambulatory Blood Pressure Monitoring Assessment of Blood Pressure Control in Hypertension Associated with Chronic Renal Failure. Nephrol. Dial. Transplant. 1993; 8: 1169–1171
   PubMed Web of Science ®Google Scholar
• Rosansky S., Menachery S., Wagner C., Jackson K. Circadian Blood Pressure Variation Versus Renal Function. Am. J. Kidney Dis. 1995; 26: 716–721
   PubMed Web of Science ®Google Scholar
• Verdecchia P. Prognostic Value of Ambulatory Blood Pressure. Current Evidence and Clinical Implications. Hypertension 2000; 35: 844–851
   PubMed Web of Science ®Google Scholar
• Takechi S., Nomura A., Shimono H., et al. Recovery of Cardiac Norepinephrine Concentration and Tyrosine Hydroxylase Activity by the Central α1-Adrenoceptor Agonist Guanabenz in Rats with Aortic Constriction. J. Cardiovasc. Pharmacol. 1999; 33: 409–413
   PubMed Web of Science ®Google Scholar
• Wollam G., Blumenstein B., Knudtson M., Felner J., Schlant R. Time Course of Regression of Left Ventricular Hypertrophy in Treated Hypertensive Patients. Am. J. Med. 1983; 75(3A)100–110
   PubMed Web of Science ®Google Scholar
• Miyajima E., Shigemasa T., Endo T., Hishiki S., Kawano Y. Guanabenz Combination Therapy Inhibits Sympathetic Nerve Activity and Regresses Left Ventricular Hypertrophy. Cardiovasc. Drugs. and Ther. 2000; 14: 61–66
   PubMed Web of Science ®Google Scholar
• Ligtenberg G., Blankestijn P., Oey P., et al. Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure. N. Engl. J. Med. 1999; 340: 1321–1328
   PubMed Web of Science ®Google Scholar
• Klahr S., Levey A., Beck G., et al. The Effects of Dietary Protein Restriction and Blood-pressure Control on the Progression of Chronic Renal Disease. N. Engl. J. Med. 1994; 330: 877–884
   PubMed Web of Science ®Google Scholar